Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.
Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ. Holme H, et al. Among authors: costa cabral s. Sci Rep. 2018 Jul 13;8(1):10614. doi: 10.1038/s41598-018-29043-z. Sci Rep. 2018. PMID: 30006631 Free PMC article.
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.
Campbell J, Ryan CJ, Brough R, Bajrami I, Pemberton HN, Chong IY, Costa-Cabral S, Frankum J, Gulati A, Holme H, Miller R, Postel-Vinay S, Rafiq R, Wei W, Williamson CT, Quigley DA, Tym J, Al-Lazikani B, Fenton T, Natrajan R, Strauss SJ, Ashworth A, Lord CJ. Campbell J, et al. Among authors: costa cabral s. Cell Rep. 2016 Mar 15;14(10):2490-501. doi: 10.1016/j.celrep.2016.02.023. Epub 2016 Mar 3. Cell Rep. 2016. PMID: 26947069 Free PMC article.
Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.
Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ. Holme H, et al. Among authors: costa cabral s. Sci Rep. 2018 Aug 21;8(1):12771. doi: 10.1038/s41598-018-30922-8. Sci Rep. 2018. PMID: 30131505 Free PMC article.
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors.
Menon M, Elliott R, Bowers L, Balan N, Rafiq R, Costa-Cabral S, Munkonge F, Trinidade I, Porter R, Campbell AD, Johnson ER, Esdar C, Buchstaller HP, Leuthner B, Rohdich F, Schneider R, Sansom O, Wienke D, Ashworth A, Lord CJ. Menon M, et al. Among authors: costa cabral s. Sci Rep. 2019 Jan 17;9(1):201. doi: 10.1038/s41598-018-36447-4. Sci Rep. 2019. PMID: 30655555 Free PMC article.
Searching for synthetic lethality in cancer.
Brough R, Frankum JR, Costa-Cabral S, Lord CJ, Ashworth A. Brough R, et al. Curr Opin Genet Dev. 2011 Feb;21(1):34-41. doi: 10.1016/j.gde.2010.10.009. Epub 2011 Jan 20. Curr Opin Genet Dev. 2011. PMID: 21255997 Review.
CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A. Costa-Cabral S, et al. PLoS One. 2016 Feb 16;11(2):e0149099. doi: 10.1371/journal.pone.0149099. eCollection 2016. PLoS One. 2016. PMID: 26881434 Free PMC article.
Functional viability profiles of breast cancer.
Brough R, Frankum JR, Sims D, Mackay A, Mendes-Pereira AM, Bajrami I, Costa-Cabral S, Rafiq R, Ahmad AS, Cerone MA, Natrajan R, Sharpe R, Shiu KK, Wetterskog D, Dedes KJ, Lambros MB, Rawjee T, Linardopoulos S, Reis-Filho JS, Turner NC, Lord CJ, Ashworth A. Brough R, et al. Cancer Discov. 2011 Aug;1(3):260-73. doi: 10.1158/2159-8290.CD-11-0107. Epub 2011 Aug 2. Cancer Discov. 2011. PMID: 21984977 Free PMC article.
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A. Costa-Cabral S, et al. PLoS One. 2017 Apr 20;12(4):e0176578. doi: 10.1371/journal.pone.0176578. eCollection 2017. PLoS One. 2017. PMID: 28426773 Free PMC article.
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A. Costa-Cabral S, et al. PLoS One. 2016 Apr 18;11(4):e0154007. doi: 10.1371/journal.pone.0154007. eCollection 2016. PLoS One. 2016. PMID: 27088596 Free PMC article. No abstract available.
13 results